ScholarIQanswers from OpenAlex

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

PaperCitations, authors & open-access status

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials have?

ScholarIQcitation count

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials has 354 citations in the OpenAlex counts ScholarIQ stores.

When was Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials published?

ScholarIQyear

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials has 2021 year in the ScholarIQ index.

What is the open-access status of Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials?

ScholarIQoa status

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials has hybrid oa status in the ScholarIQ index.

What is the DOI of Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials?

ScholarIQdoi

The DOI for Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials is on the source record.

What is the PMID of Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials?

ScholarIQpmid

The PMID for Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials is on the source record.

What is the OpenAlex record for Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials?

ScholarIQopenalex

The OpenAlex for Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial